100 N-Glycan Microarray
Overview
100 N-glycan microarray service of CD BioGlyco helps researchers investigate the binding properties of proteins, antibodies, cell cultures, bacteria or other potential biological samples to an array of 100 basic N-glycans. The glycan microarray platform established by our company ensures that we provide customers with high-quality scientific services to accelerate their research.
Introduction
N-linked protein glycosylation is a commonly occurring co-translational and post-translational modification and it is estimated that the majority of all secreted proteins are N-glycosylated. N-glycosylation modifications play an important role in the proper folding, functional localization, and intracellular transport of proteins. In mammals, N-glycosylation is important for the regulation of embryonic development, cancer development, and immune defense. In plants, N-glycosylation is significant for many physiological processes such as cell wall formation, reproductive development and defense against pathogenic bacteria invasion.
Complex N-glycans are involved in a wide range of cellular processes in mammals, especially in intercellular interactions and immune cell functions, so they are generally considered by researchers as the preferred glycan candidates for the investigation of carbohydrate-binding-vaccines like HIV broadly neutralizing antibodies (bNAb). The basic N-glycan structures offered in our 100 N-glycan microarray could help researchers understand the binding determinants underlying antibodies or other proteins of interest.
Key Technologies
Our service for 100 N-glycan microarrays employs fundamental advanced technologies ensuring exceptional reliability and analytical performance. Central to this platform, a curated collection of one hundred chemically identified N-glycans spans wide structural heterogeneity—incorporating high-mannose configurations, hybrid architectures, and complex-type glycoforms. Multiple structures demonstrate biological significance. These glycans undergo exact deposition upon functionalized glass slides, yielding microarrays of high density. Array stability and reproducible functioning derive from printing and immobilization through proprietary methods. This permits consistent, sensitive measurement of interactions between glycans and proteins—critical for elucidating diverse biological processes.
Mapping Glycan Diversity, One Spot at a Time
CD BioGlyco provides customers with microarray service for 100 N-glycans, including 81 complex and hybrid N-glycans, 10 high-mannose N-glycans and 9 Neu5Gc-N-glycans. The service we provide include but are not limited to:
- Traditional glycan microarrays. This method requires very small amounts of test glycans to provide detailed information on the effect of glycan modification on GBP recognition.
- Shotgun glycan microarrays, a functional glycomics approach, provide for the characterization of the actual glycan ligands separated from natural sources for a specific GBP.
- Microbial glycan microarrays to examine the specificity of host factors directly involved in host-pathogen interactions.
Workflow
- Sample Preparation
Your biological samples (e.g., purified proteins, antibodies, or sera) are prepared and labeled with a fluorescent tag. This step is critical to ensure accurate detection of binding events.
- Array Incubation
The labeled sample is incubated on the 100 N-glycan microarray slide. During this step, any glycan-binding proteins in your sample will bind specifically to their corresponding glycans on the array.
- Washing and Scanning
Unbound proteins are washed away, and the array is scanned using a high-sensitivity fluorescent microarray scanner. This captures the binding signal, generating a raw data image.
- Data Analysis
The raw image data is then processed using specialized software. We quantify the binding intensity for each glycan spot, normalize the data, and perform statistical analysis to identify significant binding interactions.
- Comprehensive Report
We deliver a detailed report that includes the raw data, processed results, and a clear visualization of the binding profile. Our experts are available to help you interpret the findings and discuss their biological implications.
Publication Data
DOI.: 10.3389/fchem.2019.00833
Journal: Frontiers in Chemistry
Published: 2019
IF: 4.2
Results: This review details the development and immunological applications of glycan microarrays as essential tools for identifying glycan recognition by immune proteins. The authors describe the chemical strategies for constructing these microarrays, particularly covalent attachment methods using bifunctional linkers like AEAB and F-MAPA to immobilize diverse glycans while preserving structural integrity. They highlight how glycan microarrays enable high-throughput profiling of glycan-binding proteins (GBPs) such as siglecs and galectins, revealing their specificities for sialylated or LacNAc-containing glycans. The review emphasizes the role of these arrays in immunological discoveries, including identifying natural ligands for endogenous immune receptors, characterizing pathogen-host interactions (e.g., influenza, rotavirus), and mapping the human anti-glycan antibody repertoire. Innovations like DNA-coded arrays, Luminex bead arrays, and cell-based platforms are also discussed as emerging methods to enhance throughput and biological relevance. Overall, glycan microarrays are portrayed as indispensable for deciphering glycan-mediated immune mechanisms and advancing diagnostic and therapeutic research.
Application
- Determination of N-glycans binding partners in various biological samples
- Rapid profiling of N-glycan binding properties of proteins
- Providing important information for host immunity and infectious disease
- Understanding GBP glycan interactions involved in immunity
Advantages
- Our 100 N-glycan microarray offers an unparalleled combination of breadth and specificity, covering a diverse range of N-glycan structures critical for biological research.
- The high-throughput nature of our platform allows for the rapid and simultaneous analysis of multiple samples, significantly reducing project timelines and costs.
- Our platform demonstrates its sensitivity and reproducibility in identifying glycan-binding partners.
Frequently Asked Questions
Associated Services
Our 100 N-glycan microarray decodes functional glycan signatures across biological systems—revealing critical targets in cancer, infection, and immune regulation. To transform these insights into precision interventions, we offer N-Glycosylation Inhibitor Development Services that disrupt glycan biosynthesis or interactions through complementary strategies.
- Polyol Precursor Assembly Inhibitor Development Service
- N-Glycosylation Processing Enzyme Inhibitor Development Service
- Substrate Analog-based N-Glycosylation Inhibitor Development Service
- Blocking N-Glycan-Protein Interaction Inhibitor Development Service
CD BioGlyco offers a range of glycan microarray analysis services. These help our customers speed up their scientific research and obtain reliable data by using our microarray platform to perform highly parallel glycan expression level analysis. If you need our services, please contact us for further consultation.
Reference:
- Gao, C.; et al. Glycan microarrays as chemical tools for identifying glycan recognition by immune proteins. Frontiers in chemistry. 2019, 7: 833. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





